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Diabetic heart disease (DHD) is the leading cause of morbidity and mortality among the people with diabetes, with
approximately 80% of the deaths in diabetics are due to cardiovascular complications. Importantly, heart disease in
the diabetics develop at a much earlier stage, although remaining asymptomatic till the later stage of the disease,
thereby restricting its early detection and active therapeutic management. Thus, a better understanding of the
modulators involved in the pathophysiology of DHD is necessary for the early diagnosis and development of novel
therapeutic implications for diabetes-associated cardiovascular complications. microRNAs (miRs) have recently been
evolved as key players in the various cardiovascular events through the regulation of cardiac gene expression.
Besides their credible involvement in controlling the cellular processes, they are also released in to the circulation in
disease states where they serve as potential diagnostic biomarkers for cardiovascular disease. However, their potential
role in DHD as modulators as well as diagnostic biomarkers is largely unexplored. In this review, we describe the
putative mechanisms of the selected cardiovascular miRs in relation to cardiovascular diseases and discuss their
possible involvement in the pathophysiology and early diagnosis of DHD.
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Over the past few decades, there has been a substantial
rise in the population suffering from diabetes. According
to International Diabetes Federation, 365 million people
suffered from diabetes in 2011 and this number is ex-
pected to rise up to 552 million by 2030 [1]. Among the
vast array of long-term complications associated with
diabetes, cardiovascular diseases account for increased
morbidity and mortality among diabetic population. Al-
most 80% of deaths associated with diabetes are due to
heart disease [2]. Diabetic heart disease (DHD) is in-
creasing significantly to epidemic proportions, because
of the increasing obesity, sedentary lifestyle, lack of
exercise and aging population. Despite all the efforts and
advancement made to address this global burden, high
incidence of heart disease in diabetics remains a chal-
lenge to the clinicians. Identifying the modulators of the
disease will therefore not only lead to the development* Correspondence: rajesh.katare@otago.ac.nz
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stated.of novel and effective therapeutic interventions but also
new ways to diagnose the disease at an early stage.
MicroRNAs (miRs) are a novel family of highly con-
served, short (~18-25 nucleotide), non-coding single-
stranded RNA molecules that regulate transcriptional
and post-transcriptional gene expression [3,4]. They were
first discovered as antisense RNA in the nematode
Caenorhabditis elegans by Lee et al. [5]. Since their dis-
covery, these small and ubiquitous RNAs have been
shown to play critical roles in modulating a wide range
of physiological and pathological events [6]. Biogenesis
of metazoan miR is a multistep process that is initiated
in the cell nucleus. Most of the miRs are located within
introns of the host genes (protein-coding or non-protein-
coding) or within the 3’ untranslated region (UTR) of
mRNA genes. Some are found within host exons, while
few others are also clustered with other miRNA. miRs that
are derived from their own transcription units are located
in intergenic regions of the genome [7]. miRs genes are
transcribed by RNA polymerase II. Transcription of miR
genes by RNA polymerase II form primary transcripts
known as primary miR (pri-miR). These pri-miRs are
processed by Drosha RNase III endonuclease enzymetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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critical region 8 (DGCR8) that cleaves both strands of
pri-miR near the base of primary stem loop to produce ~70
nucleotide long precursor miR (pre-miR).This cleavage
imparts an imperfect stem-loop (hairpin loop) to pre-miR
that later represents one end of the mature miR. The pre-
miR is then actively transported to the cytoplasm by
Ran-GTP and Exportin-5 (as shown in Figure 1). Within
the cytoplasm, the hairpin loop of pre-miR is cleaved
by second RNase III endonuclease enzyme, known as
Dicer. Dicer, coupled with its binding partner TRBP
(Transactivator RNA-binding protein) specifically recog-
nizes the hairpin structure and cleaves the pre-miR into
an siRNA-like imperfect duplex (miR: miR*) that com-
prises of both the mature miR strands (miR) as well as its
complementary sequence on the opposing arm of pre-miR
(miR*). The mature miR eventually gets incorporated into
a ribonucleoprotein complex, known as RNA-induced
silencing complex (RISC) to form miR-associated RNA-
induced silencing complex (miR-RISC) while the miR*
gets degraded. The main component of RISC is Argonaute
protein which facilitates the binding of miR-RISC to the
target mRNA by guiding RISC to recognize the target
mRNA having complementary sequence to perform gene
silencing. The mechanisms by which miRs regulate gene
expression and protein translation are: 1) mRNA cleavage
by binding to perfectly complementary sequence. 2) The
alternative and more common mechanism is by binding
to partially complementary sequence in 3’UTR of target
mRNA, leading to repression of protein translation [3,8].Figure 1 miR biogenesis and mRNA silencing mechanisms.However, recently, miRs have also been shown to upregu-
late translation process during the arresting phase of cell
cycle. Intriguingly, miRs oscillate between repression and
activation of translation in a cell cycle; repressing transla-
tion in proliferating phase while mediating activation of
translation in G1/G0 arresting phase of cell cycle [9,10],
thereby fine tuning the translation of multiple target
mRNAs. This could possibly explain the differential and
temporal expression of miR in a variety of cardiac diseases
suggesting that miRs play an essential role in regulating
the pathogenesis of these diseases. A single miR can
modulate complex pathological processes by acting on
multiple targets (known as pleiotropic effect), thereby
producing different and sometimes opposite functions
depending upon the time-point of the disease. Table 1
describes the pathological role and targets of the most
important cardiovascular miRs.
Apart from their role in regulating the gene expression,
miRs are also released in to the circulation in various
packaged forms like encapsulated in microparticles (exo-
somes, microvesicles and apoptotic bodies) [30,57,58]
or in complexes with RNA-binding proteins such as
Argonaute2(Ago2) [59] or lipoprotein complexes with
HDL [60]. These forms prevent the degradation of
miRs in circulation and hence make them stable in cir-
culation. Recently, miRs are gaining a lot of interest as
the diagnostic biomarkers of several chronic diseases
such as diabetes, cancer and cardiovascular diseases
because of their high stability in the circulation and
reproducibility of the results along with consistency
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date, they have not been investigated as diagnostic tool
for DHD. This review mainly focuses on describing the
pathological role of selected cardiovascular miRs that
could be involved in the pathogenesis of DHD along
with their salutary aspects for early detection of DHD.
Diabetic heart disease
The term “Diabetic heart disease’ (DHD) refers to the
myocardial disease that develops among people with
type 1 and type 2 diabetes. DHD is a conglomeration of
coronary heart disease (CHD) or coronary artery disease
(CAD); Heart Failure (HF); cardiac autonomic neuropathy
(CAN); and/or diabetic cardiomyopathy (DCM) [62] and
is characterized by the presence of structural, molecular
and functional changes.
Prevalence of DHD
Diabetes is an independent risk factor for heart disease
and indeed, diabetics are at a greater risk of developing
heart disease as compared to those without diabetes.
People with diabetes tend to develop heart disease at a
younger age than the age-matched non-diabetic popula-
tion, which is mainly because of the presence of other
co-morbidities in diabetic individuals. Importantly, the
heart disease in diabetics remains largely asymptomatic
which restricts its early detection [63]. Several epidemio-
logical and clinical studies have shown a higher preva-
lence of heart disease among population with type 1 or
type 2 diabetes [64] as compared to non-diabetic indi-
viduals [65]. The prevalence of diastolic dysfunction was
found to be as high as 40-60% in individuals with type 2
diabetes [66,67]. Recently, a seven-year prospective cohort
study involving patients with longstanding type 1 diabetes
showed a prevalence of myocardial dysfunction in 14.5%
and chronic HF in 3.7% of the patients along with an
annual incidence of 0.1% and 0.02%, respectively [68]. The
risk of developing HF is magnified almost twice in indi-
viduals with diabetes than those without diabetes [69,70].
In addition, the combination of diabetes and HF is also
associated with increased mortality rates. Studies revealed
that even after adjusting concomitant risk factors, such as
hypertension, CAD, obesity, etc., diabetes remain an
independent and discrete risk factor for the develop-
ment of heart disease [71,72]. Evidence of increased risk
of HF in diabetic population was also well documented
in the Framingham study which showed a 2 fold in-
creased risk in diabetic men and a 5 fold increased risk
in diabetic women as compared to age-matched control
subjects [71].
Molecular alterations in DHD
DHD is often unrecognized in the early or subclinical
stage due to the absence of pathognomonic signs. The earlystage of DHD is usually asymptomatic and all the myocar-
dial changes start at the molecular level. At this stage, there
is insignificant alteration in myocardial structure and
function that could be clinically assessed. Diabetes-
associated metabolic anomalies such as hyperglycemia,
hyperlipidemia, inflammation and insulin resistance ini-
tiate a series of molecular events in the myocardium.
These molecular events are characterized as increased
circulating free fatty acids (FFAs); enhanced oxidative
stress, advanced glycation end products (AGE); endo-
thelial dysfunction; activation of protein kinase C (PKC),
poly (ADP-ribose) polymerase (PARP) and polyol pathway
along with altered calcium homeostasis [73,74]. These
anomalies also cause dysregulation of various molecular
pathways leading to accelerated apoptosis, reduced rep-
arative angiogenesis, impaired electrical conduction and
maladaptive remodeling.
Changes in cellular signaling pathways are the early
defects that have been described extensively in several
animal models. A recent study by Erickson et al. [64]
showed alteration in myocadial Ca2+ ion channels, Ca2+
homeostatic proteins, and transcription factors due to
hyperglycemia-mediated activation of Ca2+/calmodulin-
dependent protein kinase II (CaMKII) which conse-
quently aggravate arrhythmia in diabetes. Intriguingly, a
study by Chen et al. [75] investigated hyperglycemia-
induced alteration in expression of cardiac ATP sensitive
potassium (K(ATP)) channels during the early stages of
diabetes, that might account for metabolic alterations
and cardiac dysfunction in diabetes. A reduced gene ex-
pression of (K(ATP)) channels was also observed in
heart of streptozotocin (STZ)-induced diabetic rats after
8 weeks of induction. Interestingly, the decrease in gene
expression was restored by insulin treatment, epitomiz-
ing the need for glycaemic control of diabetes at early
stage to lower the associated complications. We have
previously reported a blunted activation of VEGFR-2/
Akt/Pim-1 pro-survival signaling pathway in STZ-induced
type 1 diabetic mice which consequently resulted in in-
creased cardiomyocyte apoptosis, reduced cardiac con-
tractility and neovascularization [76]. Further, we observed
the change in expression and activity of STAT3/Akt/
Pim-1 signaling in the early stage of DCM. Of note,
these alterations started appearing in the initial stage of
the disease before the manifestation of overt failing
heart, reflecting the onset of the disease much earlier at
molecular level [77]. Intriguingly, systemic administra-
tion of Pim-1 in STZ-induced type 1 diabetic mice via
cardiotropic adeno-associated virus serotype-9 vector
[12] or administration of benfotiamine, a vitamin B1
analog at the initial stage [77] halted the progression of
the disease. Both these studies suggest that early detec-
tion and timely management can prevent the progres-
sion of heart disease in diabetic individuals.
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web of interconnected stress signaling pathways within
the myocardium that culminate with the activation of
various transcription factors, co-regulators and miRs,
leading to alterations in gene expression in diabetic heart
[78,79]. Several studies have demonstrated that aberrant
cardiac gene expression contributes to structural and
functional changes which are manifested as hypertrophy,
altered cardiac conduction, reduced contractility and
cardiomyocyte survival along with disturbances in vas-
cular homeostasis [80-82]. Using Otsuka Long-Evans
Tokushima Fatty (OLETF) rat model of type 2 diabetes,
Karakikes et al. [81] investigated the changes in cardiac
gene expression and the subsequent alteration in intra-
cellular signaling pathways in DCM. DCM was found
to be associated with hypertrophy; dysregulation of insulin
signaling pathway and glucose metabolism; and contractile
dysfunction associated with abnormal calcium handling
along with downregulation of sarcoplasmic reticulum
Ca2+ ATPase (SERCA2) protein expression. Microarray
analysis revealed a total of 838 genes to be differentially
expressed between control and diabetic hearts, of which,
272 genes were upregulated and 566 genes were down-
regulated, indicating the aberrant cardiac gene expression
in diabetes. Furthermore, adenoviral transduction of
SERCA2a gene in 60–65 week old OLETF rats resulted
in reversal of cardiac hypertrophy, fibrosis, ventricular
arrhythmias as well as contractile dysfunction, indicat-
ing the improvement of myocardial performance post-
SERCA2a gene transfer. In addition, a set of 76 genes
were found to be modulated with SERCA2a gene trans-
fer. Of particular interest, the expression profile of
insulin-signaling molecules (PI3K, Akt, Glut4 and PKCλ)
was restored after SERCA2a gene transfer. Similarly, over-
expression of SERCA2a in isolated rat cardiomyocytes
modulated the expression profile of major transcripts
involved in insulin signaling, glucose metabolism and car-
diac remodeling. Similarly, a recent study by Sárközy et al.
[82] on male Zucker Diabetic Fatty (ZDF) rats, a model of
metabolic syndrome, showed altered gene expression pat-
tern in diabetic myocardium, with 36 genes being upregu-
lated and 49 genes being downregulated as compared to
the normal hearts. Collectively, these findings indicate
marked alteration in cardiac gene program in diabetic
heart and therefore, augment the need to explore the
modulators of gene expression in diabetic heart.
In a study by Feng et al., glucose-induced hypertrophy
of neonatal rat cardiomyocytes was accompanied by up-
regulation of a transcriptional coactivator, p300 and acti-
vation of p300-dependent Myocyte Enhancer Factor-2
(MEF-2): MEF2A and MEF2C. MEF2 transcription fac-
tors control the expression of many fetal cardiac genes
and are reactivated in cardiac hypertrophy [83]. Intri-
guingly, blockade of p300 using curcumin and p300 siRNA(small interfering RNA) inhibited the interaction of
p300 with transcription factors, thus preventing the
upregulation of the transcription factors involved in
cardiac hypertrophy in STZ-diabetic rats. Much of our
current understanding on the regulatory phenomenon
of cardiac gene expression is at transcriptional level,
where transcriptional factors are known to govern the
activation of specific genes. However, recent studies
have uncovered another layer of cardiac gene regulation,
with a single gene being controlled by multiple regulators
at post-transcriptional level. Indeed, the transcription
factors have been found to drive the cardiac processes
via regulating the gene expression of specific miRs,
which act as post-transcriptional modulators of cardiac
gene expression [13,84].
Functional role of miRs in DHD
miRs have been defined as the “micromanagers” of gene
expression [85]. The discovery of miRs as the regulators
of multiple cardiac genes has added a new mechanistic
link between gene regulation in the normal and failing
heart at post-transcriptional level. They might act as
fine-tuners of the expression of mRNAs, by on-off
switching mechanism. Recently, miRs have been identi-
fied as a key element involved in cardiac gene remodel-
ing in diabetic heart [78]. A host of recent studies
suggests that miRs play a crucial role in the pathogenesis
of diabetes and many cardiovascular complications such
as endothelial dysfunction, angiogenesis, hypertrophy,
arrhythmia, HF and myocardial fibrosis [31,86-89] by
regulating the expression of multiple genes, as shown in
Figure 2 and Table 1. As these processes involve the
dysregulation of multiple genes, it is reasonable to
hypothesize that miRs could be implicated in the patho-
genesis of DHD. An insight in to the molecular mecha-
nisms and targets of miR involved in the pathogenesis of
heart diseases could serve as a prerequisite to explore
their role in the pathogenesis of DHD. Additionally,
molecular markers that could track the aberrant gene
expression under pathological conditions could serve as
useful diagnostic markers for early detection of disease
at molecular level. For a comprehensive understanding
of the pathological and diagnostic potential of miRs in
DHD, it is important to understand the identified miR
targets under various cardiovascular diseases.
Pathological role of miR in cardiovascular disease
A subset of miRs that are either specifically or highly
expressed in cardiac and vascular cells are termed as
cardiovascular miRs, such as miR-133, miR-1, miR-208,
miR-499, miR-126 and miR-132. Considering the largely
undetermined role of these miRs in DHD, we decided to
focus on describing the possible involvement of this sub-
set of miRs in DHD, with reference to their established
Figure 2 Pathological roles of cardiovascular miRs in heart diseases.
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logical role of each of these miRs in cardiovascular dis-
ease has been described in this section.miR-133 and miR-1
miR-133 and miR-1 are reported to be expressed specif-
ically in cardiac and skeletal muscles [90]. miR-133 fam-
ily comprises of 3 members: miR-133a-1(expressed in
cardiac and skeletal muscles), miR-133a-2(expressed in
cardiac and skeletal muscles) and miR-133b (expressed
specifically in cardiac muscles); each of which share a
common bicistronic unit with miR-1 and miR-206. How-
ever, all these miRs are expressed as separate transcripts
and exhibit different phenotypes [14]. miRs that belong
to miR-1 family are designated as miR-1-1 and miR-1-2
and are expressed in both cardiac and skeletal muscles.
[14]. Although clustered on the same chromosomal loci,
miR-133 and miR-1 are reported to play distinct roles in
modulating cellular processes in myoblasts [84,91]. miR-
133 was found to enhance myoblast proliferation by
repressing serum response factor (SRF) whereas miR-1
was found to induce myogenic differentiation by target-
ing histone deacetylase 4 (HDAC4), a transcriptional re-
pressor of muscle gene expression. miR-1 has also been
reported to control muscle differentiation by targeting
Hand2, a transcription factor that regulates expansion ofventricular cardiomyocytes [15]. Intriguingly, the expres-
sion of miR-1/miR-133 cluster is regulated by multiple
transcriptional factors: SRF [15]; MEF2 [13] and MyoD
[16]. Several studies have demonstrated the important
role of miR-1 and miR-133 in various cardiovascular dis-
eases. However, their role in DHD is still unrecognized.Cardiac hypertrophy Carè and colleagues were the first
to demonstrate the critical role of miR-133 in cardiac
hypertrophy [88]. Their study described the inverse cor-
relation of miR-133 expression and cardiac hypertrophy
in mouse and human models of hypertrophy. The report
also indicated the specific targets of miR-133 as: RhoA, a
GDP-GTP exchange protein regulating cardiac hyper-
trophy; Cdc42, a signal transduction kinase implicated
in hypertrophy; and Nelf-A/WHSC2, a nuclear factor
which is involved in cardiogenesis. Impairment in car-
diac glucose transport system has also been implicated
in the pathogenesis of failing and hypertrophic hearts
[92]. Translocation of GLUT4 to the plasma membrane
is the major mechanism of glucose uptake in cardiomyo-
cytes to maintain myocardial energetics during ischemic
stress [93]. This translocation is triggered by some
responsive factors like insulin, ischemia and exercise.
miR-133 overexpression was found to reduce the GLUT4
glucose transporter levels in cardiomyocytes along with
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protein KLF15 [94] suggesting that miR-133 may be sup-
pressing the hypertrophy through regulation of the cardiac
glucose transport system. In support of the above finding,
another study using STZ induced type 1 diabetes model
showed marked decrease in the level of miR-133a which
was associated with hypertrophy and contractile dysfunc-
tion at 2 months after induction of diabetes [95]. Further-
more, in vitro exposure of rat neonatal cardiomyocytes to
high glucose (HG, 25 mmol/L) for 48 h produced hyper-
trophic changes in cardiomyocytes along with reduced
expression of miR-133a. This was also in conjunction with
increased protein expression of the transcriptional regula-
tors of miR-133, MEF2A and MEF2C. Finally, the investi-
gators transfected the HG-exposed cardiomyocytes with
custom-synthesized miR-133a mimics and observed the
attenuation of hypertrophy along with downregulation of
SGK1 and IGF1R mRNAs, the targets of miR-133a in car-
diac hypertrophy. The study elucidated the effect of miR-
133a on HG-cardiac hypertrophy by downregulating
SGK1 and IGF1R mRNAs. In lines of the above men-
tioned evidences, it can be suggested that miR-133 play a
pathophysiological role in regulating the hyperglycaemia-
induced hypertrophy in diabetic human heart. However,
further studies are still required to investigate the po-
tential role of miR-133 in regulating cardiac hyper-
trophic changes in human failing hearts associated with
diabetes. In addition to its effects on cardiomyocytes,
miR-133 is also documented as a key regulator of vas-
cular smooth muscle cell phenotypic modulation in vitro
and in vivo by regulating the expression of SP-1, sug-
gesting its potential therapeutic application for vascular
diseases [26].
Sayed et al. [17] demonstrated the downregulation of
miR-1 as early as day 1 after transverse aortic arch con-
striction (TAC)-induced hypertrophy in mice. Later on,
gain and loss-of-function studies done by Carè et al. [88]
showed significant decrease in the expression of miR-1
in three different murine models of hypertrophy: TAC
mice, transgenic mice with AKt overexpression and
exercise-induced hypertrophy model in rats. In line with
this, adenoviral-mediated overexpression of miR-1 atten-
uated endothelin-1 induced hypertrophy in neonatal rat
ventricular cardiomyocytes along with growth-related
targets such as Ras GTPase-activating protein (RasGAP),
cyclin-dependent kinase 9 (Cdk9), fibronectin and Ras
homolog enriched in brain (Rheb). Ikeda et al. demon-
strated that miR-1 mediated regulation of hypertrophy is
through downregulation of the calcium-calmodulin sig-
naling [18]. Recent studies have revealed the critical
role of miR-1 in regulating cardiac injury by repressing
the expression of cytoprotective signaling proteins such
as heat shock proteins (HSPs), insulin growth factor 1
(IGF-1), protein kinase C epsilon (PKCε) and BCL2[96-98]. PKCε is a member of protein kinase C (PKC)
family that is known to play protective roles in cardiac
ischemia-reperfusion injury [99]. HSP60 is an anti-
apoptotic protein in mitochondria that inhibit cell
apoptosis by forming complexes with apoptotic pro-
teins like Bax, Bak and Bcl-xS [100]. Shan et al. [97]
reported the increased levels of miR-1 and miR-206 in
HG-treated rat neonatal cardiomyocytes and rat myo-
cardium through modulation of SRF and MEK1/2 sig-
naling pathway. In addition, miR-1/miR-206 was found
to repress HSP60, thereby contributing to HG-induced
apoptosis in rat cardiomyocytes. HSP60 is recently been
discovered as an important component of the defence
system against diabetic myocardial injury and its level
is reduced in the diabetic myocardium through upregu-
lation of miR-1 [97,101]. These studies provide clear
evidence for the critical role of miR-1 in the patho-
physiology of the DHD. In our previous study [12], we
reported an upregulation of cardiac miR-1 and the re-
sultant decrease in one of its target protein Pim-1 as a
causative factor for the development of cardiomyopathy
in STZ-induced type 1 diabetic mice. However, forced
expression of Pim-1 using an adeno-associated virus
serotype-9 halted the progression of DCM by activation
of the prosurvival pathway and conservation of sar-
coendoplasmic reticulum Ca2+-ATPase. In contrast, a
very recent study by Yildirim et al. [19] showed down-
regulation of miR-1, miR-499, miR-133a, and miR-133b
and upregulation of miR-21 in STZ-induced diabetic
rats. The authors suggested an inverse relationship of
these downregulated miRs with increased oxidative
stress in diabetic myocardium. Intervention with N-
acetylcysteine (NAC), an antioxidant for 4 weeks start-
ing from immediately after diabetes induction resulted
in normalization of cardiac function along with restor-
ation of expression levels of miR-499, miR-1, miR-133a,
and miR-133b in the ventricular cardiomyocytes. It
should be noted that controversies exist among these
two independent studies, which could be due to the dif-
ferent time point where the levels of miR-1 was mea-
sured as well as due to difference in the species used
between each study. These contrary reports therefore,
invite a further extensive investigation into the patho-
physiological role of miR-1 at different stages of DHD.
Arrhythmia As a consequence of ischemia, hyper-
trophy and necrosis, cardiac cells undergo electrical
reorganization which impairs the normal conduction
system within the heart, thereby increasing the risk of
developing arrhythmia. Management of arrhythmia re-
quires the better understanding about the therapeutic
targets. Studies revealed that people with diabetes are
at a much higher risk of developing atrial fibrillation
(AF) and the risk is more in individuals with history of
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levels [102]. A host of recent studies indicates the mod-
ulatory role of cardiac-specific miRs in cardiac electric
disorders. Overexpression of miR-1 and miR-133 are
reported to increase arrhythmogenesis in canine model
of non-ischemic HF due to enhanced phosphorylation
of ryanodine receptor (RyR2) by depressing the activity
of phosphatase, protein phosphatase 2A (PP2A) [20].
Yang et al. [21] demonstrated the overexpression of
miR-1 in coronary artery disease (CAD) patients pro-
viding a causal link between miR-1 and arrhythmia.
Further, injection of miR-1 in to the non-infarcted rat
heart as well as infarcted rat heart exacerbated arrhyth-
mogenesis. For this, rats were subjected to myocardial
infarction for 12 h which corresponds to the peri-
infarction period in CAD patients, and similar to the
clinical scenario the infarcted rat hearts showed high
incidence of premature ventricular beats, tachycardia
and ventricular fibrillation. Interestingly, arrhythmic ef-
fects were also observed in normal heart injected with
miR-1. Importantly, these effects were rescued by ad-
ministration of miR-1 specific antisense oligoribonu-
cleotides, demonstrating the arrhythmogenic potential
of miR-1. Post-transcriptional repression of 2 major ion
channel genes: KCNJ2 and GJA1 and downregulation
of gap junctional protein connexin-43 have been dem-
onstrated to be the mechanism for miR-1 mediated
arrhythmias [30,65].
Recent studies have shown that miRs regulate various
physiological processes in a dosage-dependent fashion
and variability occurs even among the members of same
family. Disruption of just one of the two members of
miR-1 family, miR-1-2 causes profound consequences in
the development and maintenance of cardiac physiology.
Zhao et al. [22] reported dysregulation of cardiogenesis
and widening of QRS complex in miR-1-2 knockout
mice along with abnormal cell cycle, demonstrating the
crucial role of miR-1-2 in cardiac development, electrical
conduction and cell cycle regulation. Using loss-of-function
approach, the investigators determined the potential target
of miR-1-2 as Irx5. Irx5 is a cardiac transcription factor
that functions with another repressor gene, Smyd1 to
repress the expression of potassium channel, Kcnd2 in
ventricular myocytes. A dosage-dependent regulation of
Kcnd2 by transcription factor, Irx5 is required for normal
ventricular repolarization and cardiac rhythm. miR-1-2
knockout leads to shortening of PR interval and prolonged
QRS complex due to increased activity of Irx5 which
clearly demonstrated a disruption in cardiac rhythm and
predisposition to arrhythmias. Results of these studies in-
dicate that members of the same family of miRs may work
independently to execute normal physiologic functions
and also explains that dose-sensitivity of miR-regulated
proteins is involved in development and maintenance ofnormal cardiac physiology. Electrical remodeling in DCM
has been recently ascribed to reduced expression of potas-
sium channels in myocardium and is characterized by
decreased repolarization reserve and disruption in ion
channels [103]. It is credible to mention here that under-
standing the molecular targets of miR-1 involved in the
pathogenesis of arrhythmia could also serve as potential
therapeutic targets for diabetes-mediated arrhythmia.
miR-133 has also been reported to play a pathological
role in diabetes-associated arrhythmia [27]. Overexpres-
sion of miR-133 in diabetic rabbit hearts was shown to
repress ether-a-go-go related gene (ERG) that is known
to encode for K+ channel (I(Kr)) in cardiomyocytes. Re-
pression of ERG by miR-133 causes depression of I(Kr)
and contributes to slow repolarization, thereby produ-
cing QT prolongation and the associated arrhythmias, in
diabetic hearts [101].
miR-208
miR-208a is a cardiac-specific miR that is encoded within
an intron 29 of Myh6 gene encoding alpha myosin heavy
chain (αMHC) and is regulated by αMHC. It is a member
of miR-208 family that also includes miR-208b which is
encoded within an intron 31 of Myh7 gene encoding beta
myosin heavy chain (βMHC) and expressed in cardiac and
skeletal muscles. The third member miR-499 is encoded
by intron 19 of Myh7 together with miR-1, miR-133a/b,
miR-208a/b and are recently determined to be important
regulators of genetic network in the differentiation of stem
cells in to cardiomyocytes [41].
Cardiac hypertrophy and arrhythmia The contractile
efficiency of myocardium is largely dependent on the
contractile protein, MHC. miR-208 is reported to regulate
the expression of βMHC and plays a pathological role in
cardiac hypertrophy and consequently arrhythmia. After
birth, the thyroid hormone (T3) increases the expression
of miR-208a while repressing the expression of βMHC
under normal conditions. However, under stress condi-
tions, the fetal gene system in heart is triggered and in-
creases the expression of βMHC while decreasing the
expression of αMHC without altering the expression of
miR-208a. Indeed, miR-208a functions extravagantly to
regulate cardiac contractility in response to stress such as
hypertrophic growth accompanied by fibrosis and thyroid
hormone signaling. A study by van Rooij et al. [42] dem-
onstrated that miR-208a, encoded by intron of αMHC
is required for cardiomyocyte hypertrophy, fibrosis, and
increased expression of βMHC in response to stress and
hypothyroidism in adult mice. After thoracic aortic-
banding (TAB)-induced hypertrophy, wild-type (WT)
mice showed pronounced increase in hypertrophic growth
or fibrosis. In contrast, miR-208a mutant mice showed
blunted hypertrophic growth, fibrosis and a reduction in
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mutant mice were unable to upregulate βMHC expression
in heart. Further, T3 signaling was blocked in WT and
mutant mice by feeding PTU-containing chow for 2 weeks.
Northern blot analyses in WT hearts showed a switch of
αMHC to βMHC in response to PTU whereas the mutant
amice hearts were resistant to upregulation of βMHC.
Overall, the study revealed that miR-208 is necessary for
upregulation of βMHC and cellular remodeling in heart
through a mechanism involving thyroid hormone receptor
(TR). In lines of these evidences, Callis et al. [43] reported
cardiac hypertrophy and arrhythmia in mice with trans-
genic overexpression of miR-208a, which consequently
repressed the expression of two negative regulatory target
proteins: Thyroid hormone receptor-associated protein 1
(THRAP1) and myostatin. miR-208a knockout mice
showed reduced hypertrophy, suggesting the crucial role
for miR-208a in hypertrophic growth and cardiac con-
tractility. In contrast, long-term genetic deletion of miR-
208a resulted in decreased cardiac contractility which may
possibly be due to altered cardiac conduction system
causing AF [42]. This may be attributed to altered expres-
sion of cardiac transcription factors: homeodomain-only
protein, GATA4 and the gap junction protein connexin 40
[43]. The above two studies indicate that partial blockade
of miR-208a can halt the hypertrophic growth whereas
complete knockout may initiate arrhythmia under stress
conditions. As described above it is now well established
that cardiac hypertrophy is the major contributor of the
pathogenesis in the DCM and HF. Increased expression of
βMHC has been observed in the heart of diabetic rat
[104,105]. Although there is no direct study on miR-208
in context of DHD, the general role of miR-208 in regu-
lating cardiac hypertrophic growth through MHC could
suggest its pathological role in DHD.
miR-499
Cardiac hypertrophy miR-499 is one of the three mem-
bers of myomiR family that regulate the expression of
myosin isoform in cardiac hypertrophy [106]. It is an
evolutionarily conserved muscle-specific miR embedded
within a ventricular-specific myosin heavy chain gene,
Myh7b and is highly expressed in normal heart. How-
ever, its expression is modulated in cardiac stress and
apoptosis [45]. Shieh et al. [46] investigated the expres-
sion pattern of miR-499 in human heart tissue and
transgenic mice. Microarray analysis done on human
fetal heart and liver tissues confirmed that miR-499 is
enriched in human heart. In experiments using trans-
genic mice, the elevated levels of miR-499 resulted in
cardiac hypertrophy and cardiac dysfunction in a dose-
dependent manner, which was in consistent with another
study [107] also showing the elevated levels of miR-499
in human HF. Further, thoracic aortic banding (TAB)-induced hypertrophy in TG mice overexpressed with
miR-499 demonstrated that these mice were predisposed
to increased cardiac dysfunction upon cardiac pressure
overload compared to banded wild-type controls. To
investigate the mechanistic targets of miR-499 involved
in pathogenesis of stress-induced cardiac hypertrophy,
Shieh et al. assessed the global gene expression profiles,
and observed altered levels of the immediate early stress
response genes (Egr1, Egr2 and Fos), ss-myosin heavy
chain (Myh7), and skeletal muscle actin (Acta1). Further,
gain- and loss-of- function studies in vitro confirmed the
effect of miR-499 on the immediate early gene response to
cardiac stress. These findings suggest the crucial role of
miR-499 in regulating cardiac response to stress through
regulation of stress response genes. Knowing the regula-
tory potential of miR-499 on cardiac stress response
genes, it would be interesting to find out the response of
miR-499 under diabetes induced cardiac stress.
Arrhythmia Recently, miR-499 has been investigated as
an important regulator of gene expression by regulating
the genes involved in electrical remodeling in AF [47].
miR-499 was found to repress the expression of a
small-conductance calcium-activated potassium channel 3
(SK3 channel) which is associated with AF [108]. This
channel is encoded by KCNN3 gene [109]. Transfection of
miR-499 mimic in HL-1 cells caused downregulation of
SK3 protein expression, while that of miR-499 inhibitor
resulted in upregulation of SK3 expression. This effect
may be attributed to the altered expression of KCNN3
gene by miR-499. These findings suggest a molecular
regulatory mechanism of miR-499 in electrical remodeling
in patients with AF. Having demonstrated the role of miR-
499 in the pathogenesis of arrhythmia, it is plausible that
it could be also regulate the molecular targets in diabetes-
associated arrhythmia.
Cardiomyopathy and acute myocardial infarction
miR-499 has been shown to be downregulated under
pathological conditions such as ischaemia and cardiac
remodeling. It has been found to regulate the prolifera-
tion and apoptosis in late stage of cardiac differentiation
via its effects on Sox6 and cyclin D1 [45]. In another
study, transgenic overexpression of miR-499 has been
reported to blunt cardiac apoptosis and infarction via
suppression of calcineurin-mediated dephosphorylation
of dynamin-related protein-1 (Drp1) [48]. Drp1 is involved
in initiation of apoptosis via dysregulation of mitochon-
drial fission machinery, which lead to cell death in myo-
cardial infarction [110-112]. Further, antagomir-mediated
knockdown of miR-499 aggravated cardiac remodeling as
manifested by hypertrophy and impaired cardiac func-
tions. In contrast, another group of studies showed cardiac
dysfunction in miR-499 Tg mice through regulation of
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conflicting reports on variable expression of miR-499,
Matkovich et al. [49] studied the associations between
regulatory effect of miR-499 in clinical and experimental
cardiomyopathy. The study revealed that upregulation of
miR-499 contributes to pathological aspects of human
and murine HF through direct and indirect regulation of
myocardial mRNAs and proteins; modulation of cardiac
kinase and phosphatase pathways along with post-
translational modification of myocardial proteins. Im-
portantly, the direct and indirect regulation of kinases
by miR-499 alters the phosphorylation of key proteins
which consequently influence the mitogen-activated
protein kinase (MAPK) pathway, thereby controlling
mRNA translation and apoptosis. These findings could
explain the anti-apoptotic mechanism of miR-499 shown
by Wang et al. [48], where suppression of apoptosis by
miR-499 can be attributed to its post-translational regula-
tory effect on phosphatase, calcineurin and Drp1 proteins.
Wang et al. [50] documented the negative regulatory
effect of miR-499 on Gadd45α gene expression in STZ-
induced diabetic heart and diabetic dorsal root ganglia
(DDRG). Gadd45α gene has been shown to directly
regulate the expression of 11 different proteins that are
involved in the pathophysiology of diabetes mellitus.
The study also suggested a potential link of Gadd45α
with DCM and baroreflex dysfunction. Expression profil-
ing in left ventricle tissue from 4-week STZ-induced dia-
betic rats revealed differential expression of miR-499
and Gadd45α gene. Expression of miR-499 and Gadd45α
were significantly increased at mRNA level whereas the
expression of Gadd45α was robustly decreased at protein
level in both diabetic heart and nucleus ambiguous, indi-
cating a negative regulation of Gadd45α gene by miR-
499. Results of this study therefore suggest a key role for
miR-499 in the pathophysiology of DCM. In support to
this, a recent study by Chavali et al. [113] revealed the
downregulation of miR-499 in the diabetic heart, sug-
gesting miR-499 as a putative candidate involved in the
pathophysiology of DHD.
miR-126
miR-126, also known as “angiomir” is expressed only in
endothelial cells and is encoded by intron 7 of epidermal
growth factor-like domain 7 (EGFL7) [32]. miR-126 has
been reported to regulate myocyte apoptosis [30,33],
post-MI cardiac regeneration and vascular inflammation
[34]. This endothelium-enriched miR is reported as a
key regulator in the pathophysiology of atherosclerosis,
myocardial infarction and HF. Studies revealed that
miR-126 gets regulated in the reperfused heart to insu-
late the myocardium from perturbations due to ische-
mia. Indeed, it produces cardioprotective effect by
repressing the post-infarct remodeling.Angiogenesis The vasculoprotective role of miR-126 has
been well documented by several studies [30,35,114-116].
miR-126 has been reported to maintain the vascular in-
tegrity and angiogenesis by enhancing proangiogenic
properties of vascular endothelial growth factor (VEGF)
and fibroblast growth factor (FGF) and promotes neo-
vascularization by repressing the expression of Spred-1,
an intracellular inhibitor of VEGF [36,117]. This was
evident in mice with knockdown of miR-126, where
profound vascular abnormalities and reduced survival
were observed following experimental MI. While 70%
of wild type mice survived under similar surgical condi-
tions, none of the miR-126 null mice survived beyond
3 weeks post-surgery. Consistent with these findings,
antagomir-mediated silencing of miR-126 in wild type
mice also showed impaired angiogenesis [37], confirming
the crucial role of miR-126 in maintenance of vascular
integrity and promoting angiogenesis post myocardial
infarction. Zernecke et al. [30] demonstrated the ather-
oprotective effect of miR-126 by inducing the expres-
sion of chemokine, CXCL12, which acts as a signal to
mobilize progenitor cells and as an anti-apoptotic fac-
tor. The authors showed that the delivery of miR-126
encapsulated in apoptotic bodies, to the site of athero-
sclerotic plaques in apolipoprotein E-deficient (Apoe−/−)
mice resulted in knockdown of the regulator of G-protein
signaling 16 (RGS16) and enable CXCR4, a G-protein
coupled receptor to trigger the phosphorylation of ERK1/
2, which induces the production of CXCL12. This para-
crine vasculoprotection imparted by miR-126 confers its
regulatory role in atherosclerosis and demands future in-
vestigations to assess its potential in diabetic subjects with
coronary artery disorder. Of note, diabetes is one of the
major risk factor for the development of atherosclerosis.
Heart failure Fukushima et al. [118] demonstrated re-
duced circulating levels of miR-126 in patients with
ischaemic heart disease. Interestingly, the expression
level of miR-126 was negatively correlated with the age,
New York Heart Association (NYHA) class and brain
natriuretic peptide expression, indicating its potential as
a biomarker for HF. In line with this Zampetaki et al.
demonstrated low expression levels of miR-126 in
plasma samples of type 2 diabetic patients [31], suggest-
ing it as an emerging diagnostic tool for HF in patients
with type 2 DM. Interestingly, miR-126 was also identi-
fied to be downregulated in atherosclerotic coronary
artery disease [119], one of the major cardiovascular
complication in diabetic individuals.
miR-132
Although not specifically expressed in heart, miR-132
has been recently found to play a pivotal role in car-
diac pathophysiology. miR-132 is encoded on human
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factor cAMP-response element binding protein (CREB)
in different cell types [53].
Angiogenesis Anand et al. [54] demonstrated the proan-
giogenic property of miR-132 through downregulation of
the anti-angiogenic protein p120RasGap in human umbil-
ical vein endothelial cells (HUVECs). In addition, miR-132
was found to be upregulated in human embryonic stem
cell model of vasculogenesis (a cell culture model in which
embryoid bodies derived from human embryonic stem
cells form well defined endothelial networks after 14 days
in culture) and in the endothelium of human tumors and
hemangiomas but was undetectable in normal endothe-
lium. Further, intraocular injection of miR-132 antagomir
(10 μg) induced postnatal retinal vascular development in
mice, suggesting the vasculoprotective role of miR-132.
The investigators also concluded that the phosphorylation
of CREB by angiogenic growth factors such as VEGF,
bFGF and conditioned media from different types of
tumors causes activation of miR-132 levels. The loss-of-
function studies confirmed the effect of miR-132 on endo-
thelial proliferation, tube formation in vitro and both
developmental and pathological angiogenesis in vivo via
downstream of multiple growth factors involved in regu-
lating endothelial proliferation, migration, and vascular
patterning [120]. We had recently demonstrated the
important role of miR-132 in mediating the stem cells
induced post-infarct revascularization [55]. Saphenous
vein progenitor cells (SVPs) markedly released miR-132
under stress conditions and when transplanted to the
mice hearts subjected to myocardial infarction they
activated neovascularization through the release of miR-
132 in to the surrounding region. Importantly inhibition
of miR-132 in the SVPs markedly retarded the therapeutic
effect of stem cells thus confirming the importance of
miR-132 in post-ischemic repair. Based on these evi-
dences, it is plausible that the angiogenic and neovascu-
larization effect of miR132 overexpression could be
beneficial in post-ischaemic vascular reparative process
in diabetic HF.
Cardiac hypertrophy Conversely, miR-132 along with
miR-212 was found to be upregulated in cardiomyocytes
following hypertrophic stimuli [56]. miR-212/132 null
mice were protected from pressure-overload-induced
HF, whereas cardiomyocyte-specific overexpression of the
miR-212/132 family promoted pathological cardiac
hypertrophy, HF and death in mice. This effect is at-
tributed to their direct effect on anti-hypertrophic and
pro-autophagic FoxO3 transcription factor which hyper-
activates the pro-hypertrophic calcineurin/NFAT signaling
and thereby impaired the autophagic response upon star-
vation. These controversial reports could be justified bythe different targets of miR-132 at different time-points of
the disease. Overexpression of miR-132 due to hypertrophic
stimuli suggests its role as a mediator to initiate cardiac
gene reprogramming that can promote angiogenesis after
ischaemic insult. However, experimental and clinical
studies at a larger extent are required to support these
speculations.
Other miRs in DHD
In addition to the cardiovascular miRs reviewed above, a
number of other miRs, not restricted to cardiovascular
system have also been implicated in the pathophysiology
of DHD. Although reflecting a more ubiquitous expres-
sion profile, recent studies have linked their misex-
pressed signatures with the etiology of DHD. Several
groups have implemented microarray technology to ana-
lyse the expression pattern of miRs in murine and/or
human diabetic and non-diabetic heart [113,121-123].
Shen et al. [121] provided strong evidence of activation
of MAPK signaling pathway at hypertrophic stage in dia-
betic mouse heart and in cardiomyocytes exposed to
HG. The important finding was that p38, a member of
MAPK pathway was found to regulate the expression of
miR-373 in glucose-induced cardiomyocyte hypertrophy.
Further, hypertrophic cardiomyocytes transfected with
miR-373 mimic showed repression of MEF2C, a tran-
scription factor known to be involved in cardiac hyper-
trophic growth [83]. Taken together, the study revealed
that miR-373 is transcriptionally regulated by p38 MAPK
and miR-373 can protect against glucose-induced hyper-
trophy by repressing the hypertrophic protein, MEF2C.
A recent study determined the levels of miRs using Insu-
lin2 mutant (Ins2+/−) Akita mice model of DCM. Among
the other described miRNAs, miR-223, an anti-inflammatory
and cardioprotective miR was also found to be downregu-
lated. The increased level of pro-inflammatory TNFα and at-
tenuation of anti-inflammatory mediator, IL-10 in Akita
hearts were in line with the downregulation of miR-223
[113]. However, another study points to a different role of
miR-223 in diabetic heart [122]. Quantitative miR expres-
sion analyses of left ventricular biopsies from the type 2
diabetic patients with left ventricular dysfunction revealed
the upregulation of miR-223. Adenoviral-mediated over-
expression of miR-223 in neonatal rat ventricular myocyte
(NRVM) was found to increase the cellular glucose up-
take, an effect which was independent of phosphoinositide
3-kinase (PI3K) signaling or AMP Kinase activity. Indeed,
miR-223 overexpression-induced Glut4 protein expres-
sion in cardiomyocytes was required for increased glu-
cose uptake. Furthermore, miR-223 inhibition in vivo
using mmu-miR-223 inhibitor administered to ten week
old C57BL/6 male mice at a dose of 80 mg/kg resulted
in significant decrease in Glut4 expression. These gain
and loss-of-function experiments demonstrated the
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The upregulation of miR-223 in the insulin resistant
human heart can be explained as the adaptive response
of miR-223 to restore the Glut4 expression and normalize
the glucose metabolism in diabetic heart. These observa-
tions are also in concordance with the idea that miRs act
as stress responsive elements and are responsible for
modulating the cellular phenotypes under different patho-
physiological conditions [124].
Elegant work by Greco et al. [123] identified the dys-
regulation of 6 miRs (miR-34b, miR-34c, miR-199b,
miR-210, miR-223 and miR-650) in left ventricle biopsies
obtained from diabetic patients with heart failure (D-HF)
compared to the non-diabetic patients with heart failure
(ND-HF), indicating specific pathogenetic mechanisms
differentiating D-HF from ND-HF. The hypoxia-inducible
factor (HIF) signaling pathway was found to be activated
in D-HF patients, determined by the increased levels of
HIF 1α mRNA in D-HF biopsies when compared to ND-
HF. Of note, miR-210 is the downstream target of HIF 1α,
a transcription factor that response to reduced O2 level
and thereby activates an alternative cellular mechanism of
ATP synthesis via upregulation of gene expression. Blu-
mensatt and colleagues [125] demonstrated that an ele-
vated secretion of activin A, an epicardial adipokine
released by the epicardial adipose tissue (EAT) contrib-
uted to the inhibition of the Akt/GLUT4 pathway through
upregulation of miR-143 in adult rat cardiomyocytes
(ARC) that were exposed to the conditioned media (CM)
generated from EAT of the patients with type 2 diabetes.
Insulin-dependent Akt/Glut4 signaling pathway mediates
cardiac glucose uptake by promoting the translocation of
the glucose transporter GLUT4 to the plasma membrane.
These findings revealed that upregulation of miR-143 in
EAT by Activin A cause post-transcriptional gene silen-
cing of oxysterol-binding protein-related protein 8 (ORP8)
that resulted in inhibition of the insulin-mediated phos-
phorylation of Akt/eNOS-signaling pathway. The authors
extended these findings to another study using human
vascular smooth muscle cells, wherein the upregulation of
miR-143 was also found to impair the insulin signaling via
downregulation of ORP8 [126].
miR-301a was found to directly modulate the expression
of potassium channel Kv4.2 at post-transcriptional level in
right and left ventricles of diabetic (db/db) mice [127].
Using loss-of-function and gain-of-function approach in
rat cardiomyoblasts (H9C2 cells) as an in vitro model, it
was demonstrated that miR-301a directly regulate Kv4.2
by binding to Kv4.2 3’-UTR region. The observations in
the in vitro model were consistent with the findings in the
db/db mice ventricles where a significant increase in the
expression of miR-301 and reduction in Kv4.2 expression
showed a depleted repolarization reserve in the diabetic
hearts was observed, suggesting the central regulatorypotential of miR-301a in electrical cardiac conduction
in diabetes.
miRs have also been linked to diabetes-mediated mito-
chondrial dysfunction which plays a credential role in
the consequence of DCM. In a recently published article
[128], miR-141 has been found to regulate the expres-
sion of IMM (inner mitochondrial membrane) phos-
phate transporter solute carrier family 25 member 3
protein (Slc25a3) in type I diabetic mice, treated with
multiple low-dose STZ for 5 weeks. Slc25a3 is a trans-
membrane protein which is essential for ATP production
as it provides inorganic phosphate from cytoplasm to
the mitochondrial matrix [129,130]. Another protein,
NADPH oxidase 4 (NOX4) has also been reported to be
deregulated in diabetic heart [131]. Several recent stud-
ies demonstrated the upregulation of NOX4 expression
under oxidative stress induced by hyperglycemia and
hypercholesterolemia [132-134]. miR-25 has been re-
cently evolved as a post-transcriptional gene silencer of
NOX4 by directly targeting its 3′ UTR region. Initially,
it was implicated in the regulation of insulin biosynthesis
and NOX4 expression in diabetic nephropathy [132,135].
However, recently, miR-25 has been found to repress
NOX4 expression in hypercholesterolemia-induced myo-
cardial dysfunction rats [133]. In this study, authors
showed a significant downregulation of miR-25 with a par-
allel upregulation of NOX4. Further, transfection of a
miR-25 mimic into primary cardiomyocytes decreased
oxidative stress, while a miR-25 inhibitor resulted in an
upregulation of NOX4 protein and an increase in oxida-
tive stress, suggesting the cardioprotective effect of miR-
25 against oxidative stress. Although the role of miR-25 in
diabetic myocardium still remains to be elucidated, since
diabetes is a major inducer of oxidative stress, it is
plausible that miR-25 would have similar functions in
diabetic heart. Like miR-1, miR-25 has also been re-
ported to repress the postnatal expression of Hand2 in
cultured cardiomyocytes and in mouse hearts in vivo.
In contrast, activation of calcineurin/Nfat signaling
pathway under cardiac stress, resulted in Nfat-mediated
transcriptional activation of the Hand2 gene and Nfat-
mediated transcriptional repression of miR-25, which
reawaken the expression of Hand2 genes, cardiac re-
modeling and HF [136].
Although the pathophysiological role of miRs remains
fragmental, several studies discussed herein prompt the po-
tential role of miRs in the pathophysiology of DHD. Given
that miRs regulate cardiac gene expression and are released
in to the circulation in heart disease, it may be speculated
that they can act as both mediators and diagnostic bio-
markers in DHD. Furthermore, understanding their release
mechanism under pathological conditions as well as their
regulatory role in cardiac gene expression may shed light
on the mechanistic properties of miRs in DHD.
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Although the research to clarify the expression and re-
lease of tissue-specific miRs into circulation is still in its
infancy, it may be speculated that there are two major
mechanisms that play important roles in regulating the
expression and release of miR: A) “On/off switch mech-
anism” to control which gene is to be expressed. B)
“Volume control mechanism” that increases or decreases
the level of miR to be released in to the circulation
(Figure 3). However, these mechanisms may be modu-
lated under pathophysiological conditions like stress,
HG, etc., due to activation of diverse signal transduction
pathways [42,137]. Activation of signal transducers modu-
lates the miRs that are key regulators of cardiac transcrip-
tion [138]. Since miRs are known to regulate the gene
transcription pathways by acting on specific mRNAs tar-
gets, they could modulate the transcription of regulatory
proteins that further regulate the expression and release of
specific miRs. Consequently, there is altered expression of
genes encoding proteins that regulate the expression of
miRs. A recent study [139] suggests that cardiac expressed
miRs regulate the expression of other cardiac miRs due to
their transcriptional modulation potential. Furthermore,
cardiac miRs have been reported to initiate direct cardiac
reprogramming to compensate the structural and func-
tional loss to cardiac tissue after injury [140].
Since, diabetic heart disease is associated with al-
tered cardiac gene expression, it may be reasonable to
hypothesize that this miR-mediated cardiac reprogram-
ming via On/Off switch mechanism and Volume control
mechanism may trigger the transcription of specific pro-
teins that are documented to regulate the expression of
their specific miRs (as discussed in Table 1) via On/Off
switch mechanism.
Role of miRs in cardiac regeneration
Cardiac injury in diabetes is associated with inadequate
regeneration, accumulation of excessive fibroblast and
subsequent genetic alterations which impair the normal
structure and function of the heart. An approach that
can repopulate the injured heart with new and functional
cardiomyocytes could be an ideal way to treat cardiac
injury. Cardiac gene reprogramming could have the po-
tential for regeneration of cardiomyocytes. miRs have been
demonstrated to play crucial role in cardiac muscle de-
velopment and differentiation (Table 1).
Recently, miR-92a and miR-210 are reported to play
an important role in myocardial neovascularization, that
may help in vascular repair after MI [141]. In addition,
transplantation of mesenchymal stem cells (MSCs) that
were overexpressed with miR-126 was shown to enhance
angiogenesis in the infarcted myocardium of mice via
AKT/ERK-related pathway [142]. Intriguingly, exogenousadministration of hsa-miR-590 and hsa-miR-199a to neo-
natal and adult rat cardiomyocyte markedly stimulated
proliferation and promoted cardiac repair. In vivo injec-
tion of the synthetic form of these miRs into the left
ventricle of neonatal rats produced similar increase in pro-
liferated cells even in the differentiated cells, suggesting
the cardiac regenerative potential of hsa-miR-590 and
hsa-miR-199a. Moreover, these miRs were able to boost
the normally ineffective myocardial repair that occurred
after MI [143]. Besides its role in cardiac pathophysiology,
cardiac-specific miR-499 has been shown to regulate the
differentiation and proliferation of human cardiomyocyte
progenitor cells by repressing histone deacetylase 4 and
Sox6 proteins [51]. miR-499 mediated cardiac differenti-
ation has also been reported in human embryonic stem
cells [144] and bone marrow mesenchymal stem cells
[145]. Intriguingly, the combination of miR-1, miR-133,
miR-208 and miR-499 in the presence of JAK inhibitor I
were found to exhibit reprogramming potential by con-
verting cardiac fibroblasts to cardiomyocytes (Figure 3)
[140,146]. As stated above DHD remains asymptomatic
for long time and when diagnosed at the late stage, a sig-
nificant number of functional cardiomyocytes are replaced
by fibroblasts. Therefore, reprogramming of fibroblasts to
functional cardiovascular cells using miRs offers an excit-
ing opportunity for cardiac regenerative therapy in people
with diabetes.
Can miRs be used as a clinical diagnostic tool for DHD?
Recent studies have clearly shown that heart disease in
diabetes develops at a much earlier stage before it is
clinically diagnosed and therefore, timely management
may halt the progression of the disease [12,76,77]. Dia-
stolic dysfunction in diabetes occurs as a consequence of
molecular changes at gene level. These changes are at-
tributed to the time-dependent change in cardiac gene
expression [23,147]. Therefore, an attempt to diagnose
the disease at molecular level can be a valuable strategy
towards effective therapeutic management in patients
with DHD. However, this requires the development of
effective diagnostic tool for the early diagnosis of the
disease. Currently, there are no specific and reliable tools
to detect the early stages of the disease. The available
clinical diagnostic tools such as echocardiography, cor-
onary angiography and levels of circulating biomarkers
can only diagnose established disease [148]. Recently de-
veloped non-invasive multi-slice computed tomography
angiography can be used to detect heart disease in
asymptomatic type 2 diabetic patients, however, it has
disadvantages of high radiation exposure and costs
[63,149]. Echocardiography has been considered as a
choice of non-invasive test to examine the structural and
functional alterations in heart diseases. However, this
method has few limitations that restrict its use as a
Figure 3 Proposed mechanism of modulated expression and release of cardiovascular miRs under pathophysiological conditions.
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diastolic dysfunction is often not identified in patients
with pseudonormal transmitral flow due to high left
atrial pressure, thus limiting the use of echocardiography
for accurate diagnosis of myocardial dysfunction in such
group of patients [150]. Moreover, detection of systolic
dysfunction has been found to be more challenging in
human studies using echocardiography due to insensitivity
of standard parameter of systolic function, ejection frac-
tion (EF) [151]. In addition these advance methodologies
requires the patient to visit the specialty centre.
Conventional circulating biomarkers such as aspartate
aminotransferase, total lactate dehydrogenase, CK and
CK-MB are no longer recommended in clinical diagnosis
of cardiac injury due to their low sensitivity, less preci-
sion, wide distribution in many tissues and relatively
limited specificity for the disease [152]. Cardiac tropo-
nins (cTn) have been widely used ‘gold standard’ bio-
markers in clinical assessment of myocardial injury. The
major limitations with conventional cardiac troponin is
its poor sensitivity and doesn’t change unless there issubstantial damage in the heart such as myocardial in-
farction [153], presenting low serum concentrations in
the early hours after the onset of chest pain [154]. Re-
cently developed High-sensitivity cardiac troponin assays
(Hs-cTn) and copeptin have shown a higher diagnostic
accuracy as compared to conventional cTn [155,156].
However, these biomarkers can be used only in the
established disease settings [154,156]. In a clinical study
[150] carried out on type 2 diabetic patients, the diag-
nostic potential of circulating brain natriuretic peptide
(BNP) on systolic and diastolic function was examined.
It was found that BNP and echocardiography were not
sufficiently sensitive to identify the subclinical dysfunction,
thereby augmenting the need for more sensitive bio-
markers. Another major limitation of these biomarkers is
their specificity to the disease, especially in elderly patients
with acute myocardial infarction (AMI) [152]. Accurate
diagnosis of AMI in geriatric population is a daunting
challenge due to various co-morbidities, such as end-stage
renal disease, chest discomfort and only slight elevation in
circulating troponin levels [157]. In addition, non-specific
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such as thrombotic acute coronary syndrome (ACS), con-
gestive heart failure (CHF) as well as their low serum
levels in elderly patients with renal failure further chal-
lenge its diagnosis potential for AMI [158]. Elderly pa-
tients comprise about one-half of the diabetic population
[159,160] and AMI impose a major complication among
diabetics. So the overall reliability on diagnosis per-
formance of these biomarkers in diabetic population is
unknown [161]. A clinical study by Ambhore et al.
[162] demonstrated that non-invasive techniques like
electrocardiogram (ECG) failed to diagnose the non-
ischaemic cardiomyopathy in diabetic subject with nor-
mal coronary artery, indicating the importance of an
accurate and reliable diagnostic tool for diabetic patients.
Collectively, these shortcomings augment the discovery of
highly specific and sensitive biomarkers for the detection
of DHD. In this respect, circulating cardiovascular miRs
have gained considerable interest as potential diagnostic
biomarkers for the detection of cardiovascular diseases.
An overview of clinical studies suggesting the diagnostic
potential of miRs in diabetic patients is shown in Table 2.
The discovery of miR as regulators of molecular tar-
gets involved in pathogenesis of cardiovascular diseases
has uncovered a new and exciting way for the diagnosis
of DHD. However, our knowledge on which miRs are al-
tered in DHD is largely incomplete. Tissue-specific miRs
have recently been detected in circulation and exhibit
unique expression pattern in disease states. Only a few
years ago, miRs were detected in serum and plasma in a
remarkably stable form even under different conditions,
such as, boiling, high/low pH, incubation for long time
at room temperature and multiple freeze-thawing cycles
[168,169]. Due to their stability in different human fluids
and the ease by which they can be detected quantita-
tively, they have been highlighted to be used as potential
diagnostic biomarkers for cardiovascular diseases such
as myocardial infarction, coronary artery disease, and
HF [71,170].
Sudden induction of myocardial cell death is reported
to induce the immediate release of cardiovascular miRs
into circulation where they can be detected at the initial
stage of AMI [171,172]. Several groups have studied the
diagnostic performance of circulating cardiovascular
miRs in heart diseases although their role in DHD is yet
to be explored. A consistent elevation in plasma levels of
four cardiac miRs (miR-1, -133, -208a and −499) was ob-
served in AMI patients within few hours after the onset
of symptoms for infarction [172-181]. Wang et al. [171]
documented the elevated plasma levels of these cardiac
specific miRs in rat models of AMI as well as in AMI
patients. While the level of miR-1, -133 and −499 were
expressed at very low level, miR-208 was not at all de-
tected in the plasma of healthy individuals. Interestingly,miR-208a was readily detectible in 91% patients with
AMI within 4 h of sample collection while parallel cTnI
was detected only in 85% of patients. This study suggests
the superiority of miRs in diagnosing AMI at an early
stage when compared to troponin. Long et al. [182]
compared the plasma levels of miR-1 and −126 against
cardiac troponin I (cTnl) in patients with AMI. The
expression pattern of miR-1 and −126 were found to be
similar to cTnI levels. Strikingly, in another study the
plasma peak concentration of miR-1 and −133 was found
to be significantly higher when compared to cTnI after 2 h
of the onset of chest pain [174]. These evidences suggest
that the circulating cardiovascular miRs could be sensitive
and more specific markers for the diagnosis of AMI.
Geriatric patients with non-ST segment elevation myo-
cardial infarction (NSTEMI) present atypical symptoms
and inconclusive ECG due to various co-morbidities
such as left bundle-branch block without chest pain
[183], ECG changes due to the presence of cardiac pace-
maker [183] as well as due to coexistence of chronic is-
chemic cardiomyopathy [184]. As a consequence, aged
population have higher incidence of unrecognized AMI.
Recently, miRs are also reported to exhibit greater sensi-
tivity and specificity than conventional cTn and Hs-cTn
biomarkers for geriatric population where cTn levels are
low and not reliable for detection and prognosis of
NSTEMI in elderly population [158,185]. Supporting
this, a recent study by Olivieri et al. [186] investigated
3–10 fold increase in plasma levels of miR-1, miR-21,
miR-133a and miR-423-5p along with >80-fold elevation
of miR-499-5p level in NSTEMI patients as compared to
control subjects. Interestingly, the expression of miR-499-
5p and miR-21 was significantly increased in NSTEMI
patients as compared to CHF patients. These miRs were
able to differentiate between NSTEMI elderly patients,
CHF patients as well as control individuals where their
diagnostic accuracy was found to higher than cTn, sug-
gesting their greater sensitivity and specificity for diag-
nosis of AMI as compared to cTn.
Vascular complications in diabetes start with impaired
angiogenesis and endothelial dysfunction which lead to
atherosclerosis at later stage. Endothelium-expressed
miRs: miR-126 and miR-132 are recently documented
to be altered significantly in diabetes and HF
[31,55,56,118,119], which suggests their potential to
be used in diabetes associated coronary artery disease.
A large prospective population-based study by Zampetaki
et al. [31] was the first study to determine the changes in
plasma miR signature in T2DM patients. Global miR pro-
filing of plasma samples obtained from the study cohort
(n = 822) identified a group of differentially expressed
plasma miRs in diabetic subjects when compared with age
and sex matched non-diabetic subjects. Of 13 plasma
miRs identified to be differentially expressed, the most
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miR-20b, miR-21, miR-24, miR-15a, miR-126, miR-191,
miR-197, miR-223, miR-320, and miR-486, which were
found to be less abundant in diabetic patients. However,
the expression of miR-28-3p was found to be moderately
increased. In addition, the differences in miR levels were
also replicated in plasma samples obtained from hypergly-
caemic LepOb mice, a type 2 diabetes mice model. Import-
antly, the expression profile of 5 plasma miRs (miR-15a,
miR28-3p, miR-126, miR-223, and miR-320) formed aunique signature pattern sufficient to correctly distinguish
between individuals with prevalent and incident diabetes
from healthy controls. Of note, plasma levels of miR-15a,
miR-126, and miR-223 were significantly reduced in
diabetic subjects compared to non-diabetics before the
manifestation of diabetes, providing evidence that the
determination of the level of these small RNA elements
in the blood samples might serve as early predictors in
diabetes and its vascular complications. In addition, miR-
126 content was also reduced in endothelial apoptotic
Figure 4 Supporting the hypothesis that miRs could be a potential diagnostic biomarker for early diagnosis of diabetic heart disease.
Heart disease in diabetes develops at a much earlier stage before it is clinically diagnosed and if undiagnosed and untreated, it may lead to HF at
later stage. Diabetes is associated with marked molecular changes in the heart produced by miRs. These molecular changes occur before any
structural and functional alteration in diabetic heart. Altered expression of miRs in diabetic heart inhibits the synthesis of essential proteins
required for the normal cardiac physiology. Parallel to this, these cardiovascular miRs are also released into the bloodstream, where they can be
easily detected as biomarkers for DHD.
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ion, concurring to its potential role as diagnostic bio-
marker for risk estimation of vascular complications in
diabetic individuals. Fichtlscherer et al. [119] studied the
relation of circulating levels of vessel wall and inflamma-
tory cell-derived miRs in CAD patients, thereby exploring
their potential as diagnostic biomarkers for patients with
CAD. They showed profound downregulation of vascular
miRs, including miR-126, 17 ~ 92 cluster (miR-17, miR-
20a, miR-92a), miR-130a, miR-221, members of the let-7
family (let-7d), and miR-21. In contrast, cardiac-specific
miRs, such as miR-133 and miR-208a were significantly
upregulated in CAD patients. In their prospective study,
the authors initially performed a high-throughput micro-
array to profile the changes in circulating miRs level in a
small number of CAD patients and healthy volunteers
(n = 8 in each group). 46 miRs were detected to be signifi-
cantly downregulated while 20 miRs were significantly
upregulated. These observations led to further analyses of
selected miRs in two distinct larger study cohorts: deriv-
ation cohort (n = 36 CAD patients versus n = 17 healthy
volunteers) and validation cohort (n = 31 CAD patients
versus n = 14 healthy volunteers). Interestingly, most of
the differentially expressed circulating miRs detected in
CAD patients of both cohorts are known to be expressedin the vasculature (particularly in endothelial cells) and in
cardiac and/or skeletal muscle cells. The reduced circu-
lating levels of endothelial miRs (miR-126) in disease
patients in both the studies was striking, because miR-126
is expected to be increased in cardiovascular disease as a
compensatory mechanism to induce vasculogenesis. In-
deed, the reduced levels of circulating vascular miRs in
CAD patients may be caused by increased uptake of these
miRs into atherosclerotic lesions. This could also be the
case in diabetic subjects with undiagnosed endothelial
dysfunction. These pioneering studies might therefore,
open the door to future investigations aiming to delineate
the intricate nature of miRs in various cardiovascular
diseases including DHD. A pictorial representation of
the use of cardiovascular miRs as diagnostic biomarkers
is depicted in Figure 4.
Future directions and conclusion
Since their discovery, cardiovascular miRs have emerged
as the key players in regulating cardiac gene expression
under normal and disease states. Given that miRs coor-
dinately regulate the complex webs of cardiac gene
networks and that DHD is associated with altered gene
expression, it is tempting to speculate that these ‘micro’
elements may control ‘macro’ phenotypes in diabetic
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biology in diabetic heart is still in its infancy, the literature
reviewed herein suggests that these miRs may have crucial
role in the pathophysiology of DHD and therapeutic ma-
nipulation of these miRs can be a useful strategy towards
the management of the disease. Furthermore, modulated
levels of these circulating cardiovascular miRs before the
clinical manifestation of disease augment the opportun-
ities to provide new clues for early detection of heart dis-
ease in diabetic subjects, for disease prognosis and for
assessing the efficacy of therapeutic interventions. How-
ever, the vision of miRs as successive therapeutic strategy
and its clinical relevance in DHD is a bit hazy due to lim-
ited knowledge about their role in DHD. As discussed in
this article, the use of different models studied, cell-types,
disease states as well as the lack of large size population
and differences in key parameters such as age, sex, and
pharmacological treatments in clinical studies could affect
and contribute to the complex phenotypes of these miRs.
Furthermore, developing miR-based therapies would be a
big challenge and several hurdles need to be crossed
before considering them for clinical treatments. Most
importantly, due of their pleiotropic profile, miRs can
target several genes, that could bring about undesired
‘off-target’ side effects. Future studies aimed at under-
standing the multiple pathways regulated by cardiovascu-
lar miRs at different stages of disease employing advanced
bioinformatics technologies are required to develop them
as innovative therapeutic targets. In addition, studies
based on larger size populations and using standardized
protocols for controlling multiple factors that could
affect the miR expression are requisite to elucidate the
scope of using cardiovascular miRs as potential diag-
nostic biomarkers for DHD. Nevertheless, additional
understanding into the regulatory mechanisms and re-
lease profile of cardiovascular miRs in diabetes would
help us to develop effective therapeutic interventions
along with early detection of DHD.
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